Toggle Main Menu Toggle Search

Open Access padlockePrints

A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease

Lookup NU author(s): Dr Sarah Marrinan, Professor David Burn



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2017 The Authors. Background: Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD. Methods: Phase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50mg once-daily (n=38) or placebo (n=20) for 7 to 9 days. Results: l-dopa exposure was similar with coadministration of camicinal compared to placebo. Median time to maximum l-dopa concentration was reduced, indicating more rapid absorption of l-dopa. Camicinal resulted in significant reduction in OFF time (-2.31 hours; 95% confidence interval: -3.71, -0.90), significant increase in ON time (+1.88 hours; 95% confidence interval: 0.28, 3.48) per day, and significant decrease in mean total MDS-UPDRS score (-12.5; 95% confidence interval: -19.67, -5.29). Camicinal treatment was generally well tolerated. Conclusions: PD symptom improvement with camicinal occurred in parallel with more rapid absorption of l-dopa. This study provides evidence of an improvement of the motor response to l-dopa in people with PD treated with camicinal 50mg once-daily compared with placebo, which will require further evaluation.

Publication metadata

Author(s): Marrinan SL, Otiker T, Vasist LS, Gibson RA, Sarai BK, Barton ME, Richards DB, Hellstrom PM, Nyholm D, Dukes GE, Burn DJ

Publication type: Article

Publication status: Published

Journal: Movement Disorders

Year: 2018

Volume: 33

Issue: 2

Pages: 329-332

Print publication date: 01/02/2018

Online publication date: 26/12/2017

Acceptance date: 05/11/2017

Date deposited: 17/01/2018

ISSN (print): 0885-3185

ISSN (electronic): 1531-8257

Publisher: John Wiley and Sons Inc.


DOI: 10.1002/mds.27259


Altmetrics provided by Altmetric


Funder referenceFunder name
Michael J. Fox Foundation